Nrx pharmaceuticals announces positive recommendation to continue enrollment in the ongoing trial of nrx-101 in patients with suicidal treatment-resistant bipolar depression

�  the independent data safety monitoring board recommended continuation of patient enrollment as planned ·  no safety or futility signals were reported in the first 50 patients ·  this patient population could represent up to 1 million bipolar depression patients in the us and represents a portion of the indication expansion recommended in recent correspondence with the fda ·  trial has been upgraded to a phase 2b/3 study that may be used for a registrational filing radnor, pa. , march 27, 2023 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage cns biopharmaceutical company, today reported  that the independent data safety monitoring board (dsmb) reviewed the safety and efficacy findings of the first fifty enrolled participants in the company's clinical trial of nrx-101 for the treatment of severe bipolar depression and subacute suicidal ideation or behavior ( www.clinicaltrials.gov  nct nct03395392).
NRXP Ratings Summary
NRXP Quant Ranking